We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Batm Advanced Communications Ld | LSE:BVC | London | Ordinary Share | IL0010849045 | ORD ILS0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 17.45 | 16.70 | 17.95 | - | 11 | 08:03:33 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Communications Services, Nec | 122.83M | -193k | -0.0004 | -436.25 | 76.09M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/7/2024 06:00 | FSE I think its a wise move, WIZ will have sales of one billion $ soon and be worth double what google offered. | wizzkid211 | |
23/7/2024 20:51 | Maybe some other competitors in here?https://www.prn | kooba | |
23/7/2024 11:27 | As far as I understand it Natlab has some great USP's. It can be used onsite at the point of need rather than in a far away lab, saving time and money. Provides results in one 'hit' for a range of likely relation diseases rather than the existing method of testing for one potential virus, then another, then another etc. It does this in 45-mins rather than days -- life saving for some conditions like meningitis. The operational cost of Natlab is lower than any known competitor as shown in the 2023 or 2024 BATM investor presentation with examples provided (cant remember which year.) You need less skilled staff to use the equipment, as it is highly automated. It all seems genuinely groundbreaking unless there are other 'me-too' solutions from competitors other than Oxford Nanopore. | resistance1 | |
23/7/2024 11:14 | If the new medical device is deemed not to be substantially equivalent to another, it must undergo clinical testing and pre-market approval before it can be marketed unless it is reclassified into a lower regulatory class. | resistance1 | |
23/7/2024 09:59 | Interesting so whilst there are future trials in Q4 2024 they say that NATlab is. Commercial Ready Prepared for production More syndromic panels to be added More patents to be registeredSo it would seem possible that there is the chance of commercial adoption before the results of further trials. It does not seem to explain what the trials are for or what the criteria of performance these trials are set to prove. | kooba | |
23/7/2024 08:48 | Sent via private message | resistance1 | |
23/7/2024 07:38 | I follow Ador on LinkedIn they do a post every month or so. You are right though any start-up looking to be bought out or attract a major partner to commercialise their offering would be reporting every titbit over socials. In fairness the London conference (the presentation deck I will share)was for pharma/medical outfits to meet potential sector investment partners. | resistance1 | |
22/7/2024 19:01 | Thx ..i thought we were looking at commercial product end of this year which would mean confirmation of efficacy in all the trials must be soon. A lot of money has now gone into a diagnostic product that seems to have missed commercial timelines given by BATM to shareholders ..the company itself ADOR never says anything at all ..no social media nothing ..same as with other BATM companies you wouldn't know they really exist accept Batm comment and a website. Nothing in terms of their place in the industry for what are important and large markets. Edgility tweets but mostly industry stuff on the markets it would like to address...Celare and ADOR and ADALTIS virtually nothing ..and then there is the smaller stuff. Most individuals have a bigger social media presence than many of these companies...weird. | kooba | |
22/7/2024 18:21 | I will see if I can dig out the Ador presentation in London from April and post | resistance1 | |
22/7/2024 18:18 | The Natlab timings I recall in the last 12 months have said the 2 remaining trials (of 3 trials in total) complete end of the year. Commercial product ready early next year — however long official sanction takes post trials. | resistance1 | |
22/7/2024 12:02 | Virus watch...India alert after boy dies from Nipah virus in Kerala https://www.bbc.com/ | kooba | |
18/7/2024 06:20 | RESIST, There are a few big shots eyeing BATM the dam will burst soon | wizzkid211 | |
17/7/2024 19:12 | Yes FSE BATM still feels under the radar due to its mixed, and some might say confused portfolio. We now need an Edgility colab or acquisition asap to fix this as Cyber has been on the commercial side. The icing on the cake will be a Natlab/Ador deal once trials have been completed at year end. frustrating that we have to wait for a lift off, but the dam must burst soon … upward. | resistance1 | |
17/7/2024 19:06 | Small caps are tipped to rise with falling interest rates. Many have significant loans (unlike BATM)and the interest payments will decrease. | resistance1 | |
17/7/2024 15:30 | The take out of this is that there is very significant demand and push from new cyber platforms and Edge solutions/platforms. It's also apparent that the revenue from this is only starting to trickle in. Some of these companies are on hefty valuations without the sales hitting the bottom line for a couple of years. BATM is the outlier in this respect as investors are ignoring the potential and valuing the company on straight sales. | fse | |
17/7/2024 15:27 | Is The Surge In Small Caps Only Just Startinghttps://x.co | kooba | |
16/7/2024 09:51 | https://x.com/batmlt | kooba | |
16/7/2024 05:30 | A few months ago, Wiz predicted that this year would be a year of more massive transition to cloud services in cybersecurity | wizzkid211 | |
16/7/2024 05:27 | Report: Google in advanced talks to acquire Israeli Wiz for $23 billion The Wall Street Journal reports that Google is close to closing its largest ever deal with Wiz – which, if implemented, would also be the largest deal in the history of Israeli high-tech. It is estimated that each of the four founders of the cyber company is expected to earn over $2 billion from the acquisition | wizzkid211 | |
15/7/2024 16:33 | Back to treeshaking I see. | kemche | |
15/7/2024 07:41 | 1 GBP = 4.6732 ILS | wizzkid211 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions